Status:
COMPLETED
Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination
Lead Sponsor:
GE Healthcare
Conditions:
Magnetic Resonance Imaging (MRI)
Eligibility:
All Genders
Brief Summary
The purpose of this study is to prospectively collect data on the pattern of use for gadolinium-based contrast agents (GBCAs) in real-life setting with special reference to Clariscan after its commerc...
Eligibility Criteria
Inclusion
- Participants may be included in the study if they meet all of the following criteria:
- Participants of all ages and both male/females
- Participants of all pathologies who require contrast-enhanced magnetic resonance (CE-MR) imaging as part of their diagnostic work up and the radiologist/physician has made the decision to use extracellular gadolinium-based contrast agents (GBCAs) as part of routine clinical practice
- Participants Who Provide informed consent to participate in study
Exclusion
- Use of liver-specific GBCAs (Primovist and MultiHance when used for liver excretion properties)
Key Trial Info
Start Date :
December 17 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 11 2019
Estimated Enrollment :
2118 Patients enrolled
Trial Details
Trial ID
NCT03455283
Start Date
December 17 2018
End Date
November 11 2019
Last Update
December 4 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Radiology and Nuclear Medicine Ludwigshafen, Otto-Stabel Str. 2-4
Ludwigshafen, Germany, 67059
2
University of Oslo, Division of Radiology and Nuclear Medicine, P.O. Box 1072, Blindern
Oslo, Norway, 0316